American University of Beirut

Lab of Dr. Ayad Jaffa

​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Link to Dr.Ja​ffa​​'s​ FMIS Profile

​​​​​​Research Area

Research program in my laboratory is translational in nature and is focused on elucidating the genetic, molecular, and cellular determinants that foster the development of diabetic vascular complications. Over the years, my laboratory has contributed significantly too much of our understanding of the involvement of the kallikrein-kinin system (KKS) in the pathogenesis of diabetic renal and vascular disease, uncovering novel mechanisms of receptor activation, signal transmission, and receptor cross talk and heterodimerization.

 

Research Focus

  • Biomarkers of diabetic complications (Diabetic Nephropathy, Atherosclerosis, and Cardiovascular Disease)​
  • Growth factors and signal transduction mechanisms​
  • Cross-talk between G-protein coupled receptors and tyrosine kinase receptors
  • G-Protein coupled receptor heterodimerization and down-stream signals
  • Proteome signature of diabetic complications​
  • Mediators of neuroinflammation and brain injury in diabetes
  • Inflammation and cardiovascular disease in diabetes
  • Heart-brain connection
  • Social Determinants of Health and CVD Risk in Diabetes
  • Mechanisms of vascular injury and cardiometabolic disorders  


​Selected Publications​

  • ​​Karam M, Faraj M, Jaffa MA, Jelwan J, Aldeen KS, Hassan N, Mhanna R, Jaffa AA. Developm​ent of alginate and alginate sulfate/polycaprolactone nanoparticles for growth factor delivery in wound healing therapy. Biomed Pharmacother. 2024 Jun;175:116750
  • Nour Massouh, Ayad A. Jaffa, and Miran A, Jaffa. Diabetes and the Social, Biologic, and Behavioral Determinants of Endometrial Cancer in the United States. BMC Cancer. Published on April 29, 24:540, 2024.​
  • Nour Massouh, Ayad A Jaffa, Miran A Jaffa*. Effect of Insulin Use and Social Determinants of Health on Non-Melanoma Skin Cancer: Results from the Behavioral Risk Factor Surveillance System. Cancer Control 31: 1-16, 2024.​​
  • Jaffa MA, Gebregziabher M, Jaffa AA*. Shared parameter and copula models for analysis of semi-continuous longitudinal data with nonrandom dropout and informative censoring. Stat Methods Med Res. Mar;31(3):451-474, 2022
  • Jaffa AA, Jaffa MA, Moussa M, Ahmed IA, Karam M, Aldeen KS, Al Sayegh R, El-Achkar GA, Nasrallah L, Yehya Y, Habib A, Ziyadeh FN, Eid AH,Kobeissy FH and Jaffa AA*. Modulation of Neuro-Inflammatory Signals in Microglia by Plasma Prekallikrein and Neuronal Cell Debris. Front. Pharmacol. 12:743059, 2021
  • Jaffa MA, Bebu I, Luttrell D, Braffett BH, Lachin JM, Hunt K, Lopes-Virella M, Luttrell L, Lyons TJ, Jaffa AA*. Longitudinal Plasma Kallikrein Levels and Their Association with the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC. Diabetes. 69 (11):2440-2445, 2020. PMCID:PMC7576572.
  • Dagher OK, Jaffa MA, Habib A, Ziyadeh FN, Jaffa AA*. Heteromerization fingerprints between bradykinin B2 and thromboxane TP receptors in native cells. PLoS One. 14(5):e0216908. 2019. PMCID:PMC6516669 

  • Plasma connective tissue growth factor levels predict myocardial infarction in the Veterans Affairs Diabetes Trial (VADT) cohort Kelly J Hunt, Miran A Jaffa, Sara M Garrett, Deirdre K Luttrell, Kenneth E Lipson, Maria F Lopes-Virella, Louis M Luttrell, Ayad A Jaffa Diabetes Care 41:840-846, 2018.
  • ​Proteome profiling in the aorta and kidney of type 1 diabetic rats. Al Hariri M, Elmedawar M, Zhu R, Jaffa MA, Zhao J, Mirzaei P, Ahmed A, Kobeissy F, Ziyadeh FN, Mechref Y, Jaffa AA PLoS One. Nov 9;12:e0187752. 2017
  • ​Multivariate Generalized Linear Mixed Models With Random Intercepts To Analyze Cardiovascular Risk Markers in Type-1 Diabetic Patients. Jaffa MA, Gebregziabher M, Luttrell DK, Luttrell LM, Jaffa AA J Appl Stat. 43(8):1447-1464, 2016
  • ​Plasma Prekallikrein is Associated with Carotid Intima-Media Thickness in Type 1 Diabetes.Jaffa MA, Luttrell D, Schmaier AH, Klein RL, Lopes-Virella M, Luttrell LM, Jaffa AA Diabetes, 65(2):498-502, 2016
  • ​The arrestin-selective antagonist AT1 receptor agonist Sar-Ile4-Ile8-AngII negatively regulates B2-receptor signaling via AT1-B2 receptor heterodimers.​ Wilson PC, Lee MH, Appleton KM, El-Shewy HM, Morinelli TA, Peterson YK, Luttrell LM,​ Jaffa AAJ Biol Chem 288 (26):18872-84 2013

Contact Us

For various questions, please try contacting us via social media first!
read more

Privacy Statement

We take data privacy seriously and adhere to all applicable data privacy laws and regulations.
read more

Copyright and Disclaimer

Written permission is needed to copy or disseminate all or part of the materials on the AUB website.
read more

Title IX, Non-Discrimination, and Anti-Discriminatory Harassment

AUB is committed to providing a safe and respectful environment to all members of its community.
read more